In this episode, Julie Yoo and Vijay Pande dive into the potential and challenges of implementing AI in healthcare. They revisit the grand challenges discussed in Part 1 of this conversation, Grand Challenges in Healthcare AI, and address new questions that have emerged, focusing on three main areas: the cost of healthcare and AI implementation, the data landscape for AI training, and patient experience. Topics covered: 00:00 - Intro 00:03 - Overview of three clusters of Part 1 questions: cost, data, and patient experience 00:30 - Vijay Pande discusses AI's potential to lower healthcare costs 03:00 - Julie Yoo examines the impact of AI on cost structure and labor 06:39 - Challenges in reducing healthcare costs in America 08:15 - The role of AI in shifting from sick care to preventative care 12:00 - Financial incentives and barriers to AI adoption among clinicians 15:39 - Emotional and practical aspects driving AI adoption in healthcare 19:42 - The importance of data sharing and the role of AI in healthcare innovation 22:36 - The data advantage (or lack thereof) of legacy healthcare companies 24:00 - Balancing AI-driven recommendations with clinician expertise 27:00 - The role of AI in enhancing patient experience through choice and automation 30:00 - Long-term vision for AI in personalized and preventative healthcare Resources: Find Julie Yoo on Twitter: https://x.com/julieyoo Find Vijay Pande on Twitter: https://x.com/vijaypande Learn more about a16z Bio+Health: https://a16z.com/bio-health/ Stay Updated: Find a16z Bio+Health on LinkedIn: https://www.linkedin.com/showcase/a16z-bio-health/ Find a16z Bio+Health on X: https://x.com/a16zBioHealth Subscribe on your favorite podcast app: https://a16z.com/podcasts/raising-health/ Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.